Gland Pharma Limited — Q1 FY25
Gland Pharma reported consolidated revenue of INR 14,070 million (+16% YoY), driven by 14% growth in the base business and Cenexi contribution.
neutral
medium
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q4 FY24
Cenexi quarterly revenue to ramp to EUR 50M in ~3 quarters
Cenexi's quarterly revenue is expected to gradually increase from EUR 40M to EUR 50M in about three quarters.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1